Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director · CHIEF EXECUTIVE OFFICER | January 31, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
PTC THERAPEUTICS, INC.
Report date January 31, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,962 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Sale · Disposed 2,320 · Balance 166,962 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 54,903 |
Reported balance
After 2023-01-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-31 · Sale · Disposed 301 · Balance 54,903 F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs.
F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 192,792 | $27.05 Strike: $27.05 | $5,215,023.60 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · derivative · entry 24 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,792 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F22 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 310 | $65.71 | $20,368.55 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 23 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F21 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.54 to $66.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 13,530 | $64.61 | $874,132.71 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 22 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,395 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F20 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.19 to $65.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,520 | $63.65 | $351,359.04 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 21 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,925 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F19 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.19 to $64.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,927 | $62.41 | $619,573.85 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 20 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,445 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F18 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.11 to $63.00 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 23,543 | $61.68 | $1,452,038.07 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 19 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,372 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F17 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.11 to $62.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 22,902 | $60.66 | $1,389,281.12 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 18 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,915 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F16 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.11 to $61.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 61,768 | $59.56 | $3,678,902.08 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 17 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,817 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F15 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.11 to $60.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 137,500 | $18.01 | $2,476,375.00 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 16 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 300 | $65.19 | $19,557.90 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 15 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F14 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.92 to $65.67 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,242 | $64.36 | $208,664.85 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 14 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,385 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F13 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.82 to $64.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 747 | $63.01 | $47,068.47 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 13 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,627 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F12 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.64 to $63.43 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,852 | $61.90 | $176,547.36 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 12 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.53 to $62.43 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,332 | $60.84 | $202,725.54 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 11 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,226 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.49 to $61.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,652 | $59.58 | $455,906.16 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,558 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.12 to $60.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 18,125 | $11.23 | $203,543.75 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,700 | $65.78 | $111,817.50 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.54 to $66.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 18,022 | $64.63 | $1,164,671.75 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,785 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.18 to $65.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,494 | $63.67 | $413,498.96 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,807 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.14 to $64.12 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 13,984 | $62.44 | $873,091.04 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,301 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.11 to $62.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 33,443 | $61.68 | $2,062,764.24 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,285 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.11 to $62.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 34,036 | $60.64 | $2,063,806.90 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,728 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.11 to $61.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 85,113 | $59.56 | $5,068,989.83 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,764 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.11 to $60.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 192,792 | $27.05 | $5,215,023.60 |
DisclosureSEC source: 0001179110-20-011800 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 7,208 | $27.05 Strike: $27.05 | $194,976.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · derivative · entry 29 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,792 Underlying: Common Stock · 7,208 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,104 | $10.85 Strike: $10.85 | $33,678.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · derivative · entry 28 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,104 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,115 | $10.85 Strike: $10.85 | $22,947.75 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · derivative · entry 27 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,115 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,590 | $10.85 Strike: $10.85 | $82,351.50 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · derivative · entry 26 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,104 Underlying: Common Stock · 7,590 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F21 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 700 | $64.82 | $45,374.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 25 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F20 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.69 to $65.21 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,200 | $64.16 | $76,992.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 24 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,785 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F19 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.68 to $64.63 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $62.47 | $6,246.50 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 23 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,985 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,300 | $61.83 | $80,375.10 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 22 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F18 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.42 to $62.34 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,100 | $60.72 | $66,796.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 21 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,385 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F17 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.22 to $61.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,808 | $59.57 | $167,258.52 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 20 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,485 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F16 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.11 to $60.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,208 | $27.05 | $194,976.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 19 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 300 | $64.71 | $19,412.10 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 18 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F15 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.68 to $64.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 500 | $64.01 | $32,005.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 17 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,385 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F14 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.68 to $64.39 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 449 | $61.88 | $27,781.88 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 16 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,885 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F13 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.58 to $62.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 600 | $60.95 | $36,568.80 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 15 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,334 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F12 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.56 to $61.54 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,255 | $59.52 | $74,693.84 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 14 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,934 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.11 to $60.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,104 | $10.85 | $33,678.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 13 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 500 | $64.42 | $32,210.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 12 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.20 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $61.89 | $24,754.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 11 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,585 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.54 to $62.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $60.68 | $24,272.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,985 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.46 to $61.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 815 | $59.52 | $48,504.73 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,385 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.11 to $59.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,115 | $10.85 | $22,947.75 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $65.12 | $6,512.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,600 | $64.41 | $103,051.20 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,185 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.81 to $64.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $63.21 | $25,284.00 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,785 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.80 to $63.36 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,200 | $61.93 | $74,312.40 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,185 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.54 to $62.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.